9:16
The IMMpulse study highlights the efficacy of risankizumab compared to apremilast in patients with moderate plaque psoriasis. With superior clinical outcomes and fewer side effects, risankizumab is shown to significantly improve patient quality of life and treatment satisfaction. This research suggests that risankizumab should be considered earlier in the treatment journey for moderate psoriasis.
Produced with Vocal Video